InspireMD, Inc. — FY2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. This is an annual report, not a standalone fourth-quarter report; separate Q4 results are not clearly provided in the filing text. Unless otherwise noted, financial amounts are in U.S. dollars.
Business context
InspireMD is a medical-device company developing and commercializing its MicroNet mesh-covered stent technology. CGuard EPS is its carotid product; MGuard Prime EPS is a bare-metal coronary stent. Both are sold internationally, but none of the company’s products was approved for sale in the United States. CGuard received a full European market launch through distributor Penumbra in 2015. The company’s neurovascular flow-diverter candidate remained in preclinical development.
Financial performance and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Revenue | $2.31 million | $2.82 million |
| Gross profit (loss) | $(0.30) million | $0.78 million |
| Gross margin | (12.8)% | 27.8% |
| Research and development | $3.64 million | $8.74 million |
| Selling and marketing | $3.18 million | $6.61 million |
| General and administrative | $6.39 million | $9.13 million |
| Operating loss | $(14.49) million | $(23.70) million |
| Net loss | $(15.59) million | $(25.10) million |
| Basic and diluted loss per share | $(2.23) | $(7.09) |
| Cash used in operating activities | $11.60 million | $19.36 million |
Revenue declined 18.1%. MGuard sales fell 42.6% to $1.61 million, partly offset by CGuard revenue of $0.70 million, up from $0.02 million in 2014. MGuard represented about 70% of FY2015 revenue. Lower research, selling and administrative spending helped reduce the net loss, but gross results weakened: inventory write-offs, product mix, lower MGuard prices and underused manufacturing capacity contributed to the gross loss. The filing reports $1.0 million of restructuring and impairment expense, including a $0.58 million impairment of the MGuard royalty buyout asset.
At December 31, 2015, cash and cash equivalents were $3.26 million, total current assets $4.63 million, and current liabilities $6.92 million. Working capital was negative $2.29 million. Total reported loan liabilities were $5.33 million ($4.23 million current and $1.10 million long-term); the loan is secured by substantially all company assets other than intellectual property. Cash decreased by $3.04 million during 2015. The company reported an accumulated deficit of $123.0 million and capital deficiency of $2.95 million.
Changes, outlook and material risks
- Management implemented cost reductions in 2015, focused development spending on carotid and neurovascular products, and shifted toward third-party distributors. R&D expense fell 58.3%; selling and marketing fell 51.9%.
- The company curtailed MGuard bare-metal development as market demand shifted toward drug-eluting stents. MGuard DES development was tabled because of limited resources; MASTER II was not resumed as an FDA registration trial.
- Management expected continued losses and negative operating cash flows until products—primarily CGuard—achieve commercial profitability. The auditor’s report includes a going-concern explanatory paragraph; management stated that available resources were insufficient to fund operations beyond May 2016 and that substantial doubt existed about the company’s ability to continue as a going concern.
- March 21, 2016 public and private offerings generated approximately $1.4 million in aggregate net proceeds, which management said would fund operations only for a short period. The filing said additional capital would be needed no later than May 2016 absent strategic or other non-dilutive funding. Further financing could be unavailable, costly or dilutive.
- Key risks include weak demand for bare-metal stents, dependence on CGuard commercial adoption and regulatory approvals, intense competition, reliance on certain single-source suppliers, and manufacturing concentration at the company’s Israel facility. Currency movements, reimbursement, and regional political or security disruptions in Israel are additional risks.
- The 2014 voluntary MGuard field action followed reports of stent dislodgements. The company resumed shipments after modifying the securement process, but distributor claims remained: one sought about $160,000; another’s potential claim was described as reasonably possible in a range from a minimal amount to €1.075 million. Separately, a service provider sought $1.965 million; management said loss or settlement was not probable but could not estimate the outcome.
- The filing also reports a NYSE MKT equity-listing deficiency plan, with compliance required by July 20, 2016. Failure to regain compliance could lead to delisting proceedings.
Most important facts for investors to verify
- Cash runway and financing needs after the March 2016 offerings, including whether the company secured additional capital before the stated May 2016 deadline.
- Subsequent cash burn, revenue trends and gross margins, especially CGuard sales and distributor orders versus MGuard declines.
- Status and financial exposure of the MGuard field-action-related distributor claims and the $1.965 million service-provider demand.
- Debt repayment obligations, collateral and covenant compliance, as well as progress toward the NYSE MKT listing requirements.
- Regulatory and clinical progress for CGuard and the neurovascular candidate, and whether planned development can be funded.